Please login to the form below

Not currently logged in
Email:
Password:

chorea

This page shows the latest chorea news and features for those working in and with pharma, biotech and healthcare.

FDA clears Teva's tardive dyskinesia drug Austedo

FDA clears Teva's tardive dyskinesia drug Austedo

The approval is the second for Austedo (deutetrabenazine) after being cleared by the US regulator for chorea - another movement disorder - in patients with Huntington's disease earlier this year.

Latest news

  • FDA approves Teva's Huntington's disease drug at second attempt FDA approves Teva's Huntington's disease drug at second attempt

    FDA approves Teva's Huntington's disease drug at second attempt. Austedo will treat fatal degenerative disorder chorea. ... Results from that trial are due later this year. "Chorea is a major symptom for many living with Huntington disease," said Teva's

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Teva suffered a knockback from the FDA last May for SD-809 when the agency rejected a marketing application for the drug as a treatment for involuntary writhing movements (chorea) associated

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    FDA turns down Teva's Huntington's disease drug. Has requested further analysis on certain metabolites of the chorea candidate. ... Teva has been knocked back by an FDA decision not to approve deutetrabenazine, its candidate drug for chorea associated

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    Teva is also testing deutetrabenazine in Huntington's chorea, and has completed a phase III study with a marketing application pending. ... It also has late-stage trials ongoing in chorea associated with Tourette's syndrome.

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    The takeover of Auspex will give the Israeli firm a product candidate called SD-809 (deutetrabenazine) that has already cleared phase III trials treatment of chorea (involuntary movements) associated with ... SD-809 is also in phase III testing for

More from news
Approximately 2 fully matching, plus 8 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles Medical Communications

Quintiles’ award-winning medical communications group sits at the heart of the enterprise. We offer a range of innovative strategic services,...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics